Your browser doesn't support javascript.
loading
How we treat Merkel cell carcinoma: within and beyond current guidelines.
Park, Song Y; Doolittle-Amieva, Coley; Moshiri, Yasman; Akaike, Tomoko; Parvathaneni, Upendra; Bhatia, Shailender; Zaba, Lisa C; Nghiem, Paul.
Affiliation
  • Park SY; Division of Dermatology, University of Washington at South Lake Union, Seattle, WA 98109, USA.
  • Doolittle-Amieva C; Division of Dermatology, University of Washington at South Lake Union, Seattle, WA 98109, USA.
  • Moshiri Y; Division of Dermatology, University of Washington at South Lake Union, Seattle, WA 98109, USA.
  • Akaike T; Division of Dermatology, University of Washington at South Lake Union, Seattle, WA 98109, USA.
  • Parvathaneni U; Department of Radiation Oncology, University of Washington, Seattle, WA 98109, USA.
  • Bhatia S; Department of Medicine, University of Washington, Seattle, WA 98109, USA.
  • Zaba LC; Department of Dermatology, Stanford University, Palo Alto, CA 94304, USA.
  • Nghiem P; Division of Dermatology, University of Washington at South Lake Union, Seattle, WA 98109, USA.
Future Oncol ; 17(11): 1363-1377, 2021 Apr.
Article in En | MEDLINE | ID: mdl-33511866
ABSTRACT
Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with a high risk of local recurrence and distant metastasis. Optimal care of this potentially life-threatening cancer is critical but challenging because physicians are often unfamiliar with its management due to rarity, and MCC management remains controversial, in part because it is rapidly evolving across multiple specialties. While guidelines offer a broad overview of management, they are often not sufficient when making decisions for individual patients. Herein, we present a literature review as well as practical approaches adopted at our institutions for staging, surveillance and therapy of MCC. Each of these areas are discussed in light of how they can be appropriately customized for prevalent but challenging situations. We also provide representative examples of MCC patient scenarios and how they were managed by a multidisciplinary team to identify suitable evidence-based, individualized treatment plans.
Lay abstract Merkel cell carcinoma (MCC) is a skin cancer with a high risk of recurrence and distant spread. Optimal care of this cancer is important. However, management is challenging because it is rare and its treatment is continuously evolving across multiple specialties. While treatment guidelines offer a broad overview of management, they are often not detailed enough to provide appropriate patient-specific assistance. Herein, we present a review of recent studies and our suggestions relevant to MCC staging, surveillance and treatment options. Each of these areas are discussed in light of how they can be appropriately customized for challenging situations often encountered by practitioners. We also provide representative examples of MCC patient scenarios and how they were managed by a multidisciplinary team to identify evidence-based, individualized treatment plans.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Carcinoma, Merkel Cell Type of study: Guideline Limits: Humans Language: En Journal: Future Oncol Year: 2021 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Carcinoma, Merkel Cell Type of study: Guideline Limits: Humans Language: En Journal: Future Oncol Year: 2021 Document type: Article Affiliation country: Estados Unidos